Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.

Niesor EJ, Magg C, Ogawa N, Okamoto H, von der Mark E, Matile H, Schmid G, Clerc RG, Chaput E, Blum-Kaelin D, Huber W, Thoma R, Pflieger P, Kakutani M, Takahashi D, Dernick G, Maugeais C.

J Lipid Res. 2010 Dec;51(12):3443-54. doi: 10.1194/jlr.M008706. Epub 2010 Sep 22.

2.

Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.

Niesor EJ.

Curr Opin Lipidol. 2011 Aug;22(4):288-95. doi: 10.1097/MOL.0b013e3283475e00. Review.

PMID:
21587074
3.

Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.

Shinkai H.

Vasc Health Risk Manag. 2012;8:323-31. doi: 10.2147/VHRM.S25238. Epub 2012 May 15. Review.

4.

An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.

Rhainds D, Arsenault BJ, Brodeur MR, Tardif JC.

Future Cardiol. 2012 Jul;8(4):513-31. doi: 10.2217/fca.12.25. Review.

PMID:
22871191
5.

Dalcetrapib: a review of Phase II data.

Robinson JG.

Expert Opin Investig Drugs. 2010 Jun;19(6):795-805. doi: 10.1517/13543784.2010.488219. Review.

PMID:
20465364
6.
7.

Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk?

Schaefer EJ.

Curr Opin Lipidol. 2013 Jun;24(3):259-64. doi: 10.1097/MOL.0b013e3283612454. Review.

PMID:
23652567
8.

The end of the road for CETP inhibitors after torcetrapib?

Joy T, Hegele RA.

Curr Opin Cardiol. 2009 Jul;24(4):364-71. Review.

PMID:
19522058
9.

Future of cholesteryl ester transfer protein inhibitors.

Rader DJ, deGoma EM.

Annu Rev Med. 2014;65:385-403. doi: 10.1146/annurev-med-050311-163305. Review.

PMID:
24422575
10.

Anacetrapib: hope for CETP inhibitors?

Gurfinkel R, Joy TR.

Cardiovasc Ther. 2011 Oct;29(5):327-39. doi: 10.1111/j.1755-5922.2010.00142.x. Epub 2010 Apr 9. Review.

PMID:
20406242
11.

Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.

Ghosh RK, Ghosh SM.

Curr Clin Pharmacol. 2012 May;7(2):102-10. Review.

PMID:
22432840
12.

Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.

Sirtori CR.

Expert Opin Investig Drugs. 2011 Nov;20(11):1543-54. doi: 10.1517/13543784.2011.614946. Epub 2011 Oct 1. Review.

PMID:
21961529
13.

Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.

Shinkai H.

Expert Opin Ther Pat. 2009 Sep;19(9):1229-37. doi: 10.1517/13543770903198451. Review.

PMID:
19663630
14.

Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.

Goldberg AS, Hegele RA.

Drug Des Devel Ther. 2012;6:251-9. doi: 10.2147/DDDT.S34976. Epub 2012 Sep 24. Review.

15.

Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?

Barter P, Rye KA.

Trends Pharmacol Sci. 2011 Dec;32(12):694-9. doi: 10.1016/j.tips.2011.07.004. Epub 2011 Nov 14. Review.

PMID:
22088767
16.

[HDL and CETP in atherogenesis].

Pöss J, Böhm M, Laufs U.

Dtsch Med Wochenschr. 2010 Feb;135(5):188-92. doi: 10.1055/s-0030-1247862. Epub 2010 Jan 15. Review. German.

PMID:
20082258
17.

Rationale for cholesteryl ester transfer protein inhibition.

Hewing B, Fisher EA.

Curr Opin Lipidol. 2012 Aug;23(4):372-6. doi: 10.1097/MOL.0b013e328353ef1d. Review.

18.

Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.

Kappelle PJ, van Tol A, Wolffenbuttel BH, Dullaart RP.

Cardiovasc Ther. 2011 Dec;29(6):e89-99. doi: 10.1111/j.1755-5922.2010.00201.x. Epub 2010 Jul 14. Review.

PMID:
20645987
19.

Safety of CETP inhibition.

Duivenvoorden R, Fayad ZA.

Curr Opin Lipidol. 2012 Dec;23(6):518-24. doi: 10.1097/MOL.0b013e32835916b3. Review.

PMID:
23010697
20.

Cholesteryl ester transfer protein inhibitors: challenges and perspectives.

Filippatos TD, Klouras E, Barkas F, Elisaf M.

Expert Rev Cardiovasc Ther. 2016 Aug;14(8):953-62. doi: 10.1080/14779072.2016.1189327. Epub 2016 May 28. Review.

PMID:
27171534

Supplemental Content

Support Center